Quotient (NASDAQ:QTNT) Rating Increased to Buy at BidaskClub
Other equities research analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Quotient from a buy rating to a hold rating in a research note on Friday, November 8th. ValuEngine raised shares of Quotient from a sell rating to a hold rating in a research note on Tuesday, November 19th.
QTNT stock opened at $9.05 on Friday. The firm has a 50 day simple moving average of $8.32 and a 200 day simple moving average of $9.03. Quotient has a 52 week low of $5.73 and a 52 week high of $11.30. The stock has a market cap of $601.24 million, a P/E ratio of -4.71 and a beta of 0.96. The company has a debt-to-equity ratio of 72.27, a quick ratio of 3.25 and a current ratio of 3.97.
In other news, major shareholder Perceptive Advisors Llc purchased 2,500,000 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was bought at an average cost of $7.00 per share, with a total value of $17,500,000.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 14.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of QTNT. Tower Research Capital LLC TRC increased its stake in shares of Quotient by 846.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,738 shares of the company’s stock worth $52,000 after purchasing an additional 6,026 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Quotient during the 2nd quarter valued at $69,000. Cadence Capital Management LLC acquired a new stake in shares of Quotient in the 3rd quarter valued at $96,000. Northern Trust Corp acquired a new stake in shares of Quotient in the 2nd quarter valued at $122,000. Finally, Trexquant Investment LP acquired a new stake in shares of Quotient in the 2nd quarter valued at $123,000. Hedge funds and other institutional investors own 73.51% of the company’s stock.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Read More: What is a bull market?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.